PHC Holdings

SciMed (Asia) Pte Ltd. is a Singapore-based company that specializes in the distribution of laboratory equipment and supplies, including cleanroom products, cell culture media, antibodies, and immunoassays. Established in 1992, the company serves various sectors such as agriculture, biopharmaceuticals, education, healthcare, industrial laboratories, medical devices, pharmaceuticals, and research life sciences. In addition to providing a comprehensive range of laboratory instruments and reagents, SciMed (Asia) offers biodecontamination and scientific services to support clients in meeting their research and scientific needs. As of July 2020, it operates as a subsidiary of PHC Holdings Corporation.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

Aiforia Technologies, founded in 2013 as a spin-off from the Finnish Institute for Molecular Medicine at the University of Helsinki, specializes in cloud-based microscopy and pathology. The company offers the Aiforia® Platform, which combines deep learning artificial intelligence with high-performance cloud computing to enhance image-based diagnostics. Aiforia's solutions aim to increase efficiency and scalability in medical image analysis, supporting pathologists and scientists in both preclinical and clinical settings. By providing highly accurate and consistent data, Aiforia facilitates new discoveries and clinical decision-making across various disciplines, including oncology and neuroscience. The platform's image-agnostic capabilities allow it to extend its applications beyond traditional boundaries, positioning Aiforia as a leader in advancing medical imaging technology.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Founded in 1996, the company focuses on innovative and long-term implantable glucose monitoring solutions that utilize advanced fluorescence sensing technology. Its flagship products, Eversense and Eversense XL, are implantable CGM systems designed to monitor glucose levels for up to 90 and 180 days, respectively. These products aim to provide users with a reliable and stable means of glucose management, enhancing their ability to live confidently and manage their diabetes effectively. The majority of Senseonics' revenue comes from international markets, reflecting its strong presence in Europe.

Lunaphore specializes in tumor analysis through innovative microfluidic chip technology, which allows for rapid and precise assays that surpass traditional methods. The company's platform facilitates the extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology with a user-friendly interface. This technology aids researchers in immunology, immuno-oncology, and neurology by identifying clinically relevant biomarker signatures, which support the development of diagnostic tools and streamline clinical trials. By improving the efficiency of cancer diagnostics and enhancing the accuracy of results, Lunaphore ultimately aims to contribute to better patient outcomes.

KAKEHASHI Inc. is a Tokyo-based company founded in 2016 that develops a software as a service (SaaS) application tailored for health insurance claim and drug history management, specifically designed for dispensing pharmacists using iPads. The company aims to bridge the gap between medical treatment and patients, reflecting its mission to connect medical care with a brighter future. As Japan faces an aging population, with projections indicating that by 2060, one in four individuals will be over 75 years old, KAKEHASHI seeks to innovate and enhance healthcare delivery. The organization's focus on leveraging Japan's advanced medical technology and systems aligns with the need for effective solutions that support healthy life expectancy in an increasingly elderly society.

Ascensia Diabetes Care Holdings AG, based in Basel, Switzerland, specializes in the development and manufacturing of blood glucose monitoring systems, lancing devices, and diabetes management software. The company focuses on enhancing the lives of individuals with diabetes by providing innovative healthcare solutions that empower patients to manage their condition effectively. As a subsidiary of Panasonic Healthcare Holdings Co., Ltd., Ascensia Diabetes Care aims to support users in taking charge of their health and well-being through its comprehensive range of products.

Millennial Net's flagship platform, MeshScape, offers highly scalable, low power, reliable wireless mesh networking capability that is beyond any conventional WSN technologies. Millennial Net also provides Wireless Energy Management and Energy Efficiency solutions focused on commercial and public building applications. Typically save 15%-30% of a buildings current energy consumption.